Rigel to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer, announced its participation in two upcoming investor conferences in September 2024. Dean Schorno, the company's CFO, will represent Rigel at:

1. The 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5th for one-on-one meetings.

2. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 10th, where he will participate in one-on-one meetings and present a company overview at 11:30 a.m. ET.

A live webcast of the H.C. Wainwright presentation will be available on Rigel's website. Founded in 1996, Rigel is based in South San Francisco, California, and is dedicated to developing novel therapies for patients with hematologic disorders and cancer.

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:

• 2024 Wells Fargo Healthcare Conference, Boston, MA
  Mr. Schorno will participate in one-on-one meetings on Thursday, September 5th.
    
• H.C. Wainwright 26^th Annual Global Investment Conference, New York, NY
  Mr. Schorno will participate in one-on-one meetings and present a company overview on Tuesday, September 10th at 11:30 a.m. ET.

To access the live webcast or archived recording of the H.C. Wainwright Conference presentation, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors: 
Rigel Pharmaceuticals, Inc. 
650.624.1232 
ir@rigel.com

Media: 
David Rosen 
Argot Partners 
212.600.1902 
david.rosen@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-participate-in-upcoming-september-investor-conferences-302233721.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

What investor conferences will Rigel Pharmaceuticals (RIGL) attend in September 2024?

Rigel Pharmaceuticals (RIGL) will attend the 2024 Wells Fargo Healthcare Conference in Boston on September 5th and the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 10th, 2024.

Who will represent Rigel Pharmaceuticals (RIGL) at the September 2024 investor conferences?

Dean Schorno, Rigel Pharmaceuticals' Chief Financial Officer, will represent the company at both investor conferences in September 2024.

When and where will Rigel Pharmaceuticals (RIGL) present at the H.C. Wainwright Conference?

Rigel Pharmaceuticals (RIGL) will present a company overview at the H.C. Wainwright Conference on Tuesday, September 10th, 2024, at 11:30 a.m. ET in New York, NY.

How can investors access Rigel Pharmaceuticals' (RIGL) presentation at the H.C. Wainwright Conference?

Investors can access the live webcast or archived recording of Rigel Pharmaceuticals' (RIGL) presentation at the H.C. Wainwright Conference through the Investor Relations section of the company's website at www.rigel.com.

What is the main focus of Rigel Pharmaceuticals (RIGL) as a biotechnology company?

Rigel Pharmaceuticals (RIGL) is a biotechnology company primarily focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer.